We're professional Percutaneous Nephroscopy manufacturers and suppliers in China, specialized in
providing high quality medical instruments with reasonable price. We
warmly welcome you to buy or wholesale bulk Percutaneous Nephroscopy
for sale here and get quotation from our factory. Percutaneous Nephroscopy,Percutaneous Nephroscopy Sheath,Percutaneous Nephroscopy Dilator,Percutaneous Nephroscope Set Tonglu WANHE Medical Instrument Co., Ltd , https://www.tlvanhurhealth.com
Long-acting anti-HIV drugs can inhibit the virus for at least four weeks
According to a recent medical study published by the British journal Nature Communications on the 7th, American scientists have demonstrated a long-acting, injectable anti-human immunodeficiency virus (HIV) in mouse experiments. That is, HIV) drugs. The concentration of the drug contained in one dose is sufficient to inhibit the replication of HIV in the blood and tissues of mice for at least one month.
HIV is a retrovirus whose reverse transcription process is carried out under the action of viral reverse transcriptase. The antiretroviral treatment adopted by humans is to transform HIV infection from a deadly condition into a controlled chronic disease. However, this also means that AIDS patients need to inject drugs every day, rely on them, and may lead to the emergence of drug-resistant HIV. If there is a drug that does not require such high frequency injections, such as weekly, monthly or bimonthly, it will be a better and more popular alternative to patients.
This time, Howard Grootman, a scientist at the University of Nebraska Medical Center, and his colleagues made a chemical structural modification of an antiretroviral drug called vlurotvir. The drug is the third HIV integrase inhibitor approved by the US Food and Drug Administration (FDA) to prevent HIV proliferation by blocking integrase and to reduce the amount of HIV in the body. The researchers added a long carbon chain to the durumvir and loaded the prodrug, an inactive compound that produces an active drug through metabolism, into a polymer. In the mouse experiment, the final formulated drug showed high antiretroviral activity for more than 4 weeks.
Although some long-acting, injectable anti-HIV therapies are still in clinical trials, many patients have begun to use dulovir. The latest prescription is to better infiltrate the drug into the cells and tissues of the virus reservoir.
This new drug requires less injection than other long-acting antiretroviral drugs currently being tested. Subsequent research will focus on the blended formulation of durum and other drugs, as well as the possibility of conducting human trials, including treatment of infected patients and prevention of infection in healthy individuals.
After antiretroviral therapy successfully blocks the pace of the disease, prolonging the drug injection cycle has become a new target for anti-HIV therapy. If you can only inject once in a month, you can at least moderately relieve the patient's daily panic reminder "Hey, the disease is behind you!" It can be said that on the basis of ensuring the efficacy, prolonging the injection cycle is to improve the quality of life. In addition to AIDS, all chronic diseases that rely on regular injections, medications, or devices to delay the progression of the disease can follow this line of thinking and conduct research on new therapies. (Reporter Zhang Mengran)